Cellectar Biosciences, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Cellectar is a clinical-stage oncology biotechnology company developing phospholipid drug conjugates (PDCs); its lead candidate is iopofosine I-131. The filing reports no revenue.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Research and development expense | $6.31 million | $4.50 million | $12.96 million | $8.39 million |
| General and administrative expense | $1.99 million | $2.94 million | $4.04 million | $5.19 million |
| Total costs and expenses | $8.29 million | $7.44 million | $17.00 million | $13.58 million |
| Net loss | $8.22 million | $7.44 million | $16.80 million | $13.57 million |
| Basic and diluted loss per share | $0.73 | $1.22 | $1.49 | $2.22 |
Margins are not meaningful given the absence of reported revenue. Interest income was $73,000 in Q2 and $197,000 for the six months, versus minimal amounts in 2022. NCI grant funding received—approximately $241,000 in Q2 and $647,000 year to date—was recorded as a reduction of R&D expense.
Cash, liquidity and capital
- Cash and cash equivalents were $5.15 million at June 30, 2023, down from $19.87 million at December 31, 2022.
- Operating cash use was $14.71 million for the first six months, compared with $10.80 million in the prior-year period. Investing cash use was nil; financing cash provided was negligible.
- Current assets were $5.61 million versus current liabilities of $6.45 million. Total liabilities were $6.98 million, primarily accounts payable and accrued liabilities and lease obligations. The filing reports no borrowing debt; lease liabilities totaled about $585,000.
- Stockholders’ equity moved from $15.51 million at year-end to a deficit of $467,000. Common shares issued and outstanding were 9.74 million at June 30; the filing also lists 8.24 million outstanding warrants, including 5.15 million common warrants exercisable at $1.96.
Changes and operating developments
Q2 R&D increased 40% year over year, mainly due to higher manufacturing and sourcing costs and increased personnel-related research costs; clinical and preclinical project costs decreased in the quarter. Six-month R&D rose 55%, reflecting increased manufacturing, clinical activity associated with the pivotal trial, and personnel costs. G&A decreased 32% in Q2 and 22% year to date, primarily due to lower professional fees and personnel costs.
The company reported a complete response in a CNS lymphoma patient and said the CLOVER-WaM pivotal study had completed site enrollment, with top-line data expected in the second half of 2023. It also described initiation of the pediatric high-grade glioma Phase 1b study as expected in Q3 2023. These are management-reported development updates, not established commercial outcomes.
Outlook, risks and unusual items
- Management said June 30 cash was expected to fund basic budgeted operations into Q4 2023. Continuing the operating plan depends on raising additional capital through equity or debt, a strategic transaction, or other means; there is no assurance funding will be available.
- The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern within one year after the financial statements were issued. Management expects continued operating losses.
- Key risks include clinical-trial uncertainty and adverse events, reliance on a sole iopofosine supplier, financing needs, and meeting Nasdaq continued-listing standards. Reported trial adverse events include cytopenias and fatigue; the filing notes infections and at least one possibly treatment-related fatality.
- The company’s lawsuit over intellectual property was resolved in November 2022; claims were dismissed and Cellectar obtained an irrevocable, non-exclusive license to the patents at issue. No material effect from other ordinary-course legal matters was anticipated.
- Management reported effective disclosure controls and no significant change in internal control over financial reporting during the quarter.
Investor verification priorities
- Verify the timing and results of CLOVER-WaM top-line data and progress of the pediatric Phase 1b study.
- Assess the pace of cash burn, available financing alternatives, and whether funding can extend operations beyond Q4 2023.
- Review clinical safety and efficacy evidence, including the risks associated with cytopenias, infections, and the reported possible treatment-related fatality.
- Monitor Nasdaq listing compliance and potential dilution from warrants, stock options, and future capital raises.
- Confirm manufacturing and supply continuity for iopofosine and the status of the company’s clinical programs and collaborations.